يحاول ذهب - حر

IRREPLACEABLE HUMAN TOUCH

BioSpectrum Asia July 2025

|

BioSpectrum Asia

The trend of virtual and remote healthcare—including diagnostics and treatment—is gaining traction globally. Telemedicine, in particular, saw a rapid acceleration during COVID-19, when in-person consultations were often avoided due to the risk of virus transmission. Both healthcare providers and patients embraced remote care as a safer alternative. According to a GlobalData survey, 56 per cent of healthcare professionals believe that the growth of telemedicine and remote care has enhanced patients’ control over their health management. Among them, 13 per cent strongly agreed, while 26 per cent remained neutral. Only 2 per cent disagreed and 3 per cent strongly disagreed, showing widespread acceptance of this shift.

- Dr Milind Kokje Chief Editor milind.kokje@mmactiv.com

IRREPLACEABLE HUMAN TOUCH

The trend is picking up significantly across Asia. Even Pakistan is exploring the use of artificial general intelligence (AGI) for diagnostics and nursing education. The Pakistan Nursing and Midwifery Council (PNMC) has partnered with a California-based AI company to address critical challenges in nursing education. The country faces a staggering shortage of skilled nurses—estimated at over 3 million—& without intervention, it would take more than 90 years to bridge this gap. AI, therefore, is being seen as a vital solution. The rise and spread of virtual care & treatment is also beneficial for the hospitals, as in several places in Asia, they are experiencing a shortage of beds. A recent report from Singapore mentioned that with rising demand for critical care, hospitals often experience a shortage of beds and experienced clinical staff, particularly for ICUs. Thus, the Singapore Health Services (SingHealth) is working on optimising the smart ICU's capacity. They can detect patient deterioration early, allowing treatments to be given even in non-ICU wards without the necessity of moving the patient to the ICU.

المزيد من القصص من BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits

US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation

US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio

Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema

A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing

Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO

Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

IIT-D and AIIMS develop swallowable microdevice for microbiome study

Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Ambitious research to develop multivalent vaccines against multiple deadly filoviruses

Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.

time to read

1 min

BioSpectrum Asia Feb 2026

Listen

Translate

Share

-
+

Change font size